Please login to the form below

Not currently logged in
Email:
Password:

ankylosing spondylitis

This page shows the latest ankylosing spondylitis news and features for those working in and with pharma, biotech and healthcare.

Gilead and Galapagos close in on filing for Xeljanz rival

Gilead and Galapagos close in on filing for Xeljanz rival

RA and the rest from other diseases such as psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and atopic dermatitis.

Latest news

  • Novartis gains label boost for Cosentyx Novartis gains label boost for Cosentyx

    Cosentyx has been in the psoriatic arthritis (PsA) market for almost four years now, and has also established itself in plaque psoriasis and ankylosing spondylitis.

  • Gilead and Galapagos JAK contender scores in RA trial Gilead and Galapagos JAK contender scores in RA trial

    The results are further good news for the partners and their inflammatory conditions contender, which is also being studied in ulcerative colitis, Crohn’s disease and ankylosing spondylitis. ... The new results for filgotinib follow close behind

  • Gilead, Galapagos JAK inhibitor clears phase II test Gilead, Galapagos JAK inhibitor clears phase II test

    A mid-stage trial of Gilead and Galapagos’ JAK1 inhibitor filgotinib has set up a phase III programme for the drug in ankylosing spondylitis as it chases down two already-marketed

  • AbbVie’s upadacitinib aces phase III trial AbbVie’s upadacitinib aces phase III trial

    even climb as high as $5bn at peak if it also shows its worth in follow-up indications like psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and atopic dermatitis.

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    Sandoz’ Zessly, a biosimilar of J&J’s Remicade (infliximab) for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.

More from news
Approximately 4 fully matching, plus 66 partially matching documents found.

Latest Intelligence

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    The two infliximab biosimilars are also included in the cost-effectiveness watchdog's ongoing appraisals of TNF-alpha inhibitors for ankylosing spondylitis and its review of Humira, Enbrel, Remicade, Cimzia, Simponi,

  • An eye towards the biobetter in South Korea An eye towards the biobetter in South Korea

    Emerging area. Marketed in 2007. RA = rheumatoid arthritis; AS = ankylosing spondylitis; CD = Crohn's disease; PA = psoriatic arthritis; PS = psoriasis;  . UC = ulcerative colitis; NHL = non-Hodgkin lymphoma; PCI = percutaneous coronary intervention

  • Gaming tackles back pain

    Built on a strong, simple strategy it used multiple channels to flood the world of men aged 18-40 with symptoms of Ankylosing Spondylitis (AS), a progressive, debilitating condition. ... With a barely pronounceable name, frequent confusion with common

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics